Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial

Autor: Baramidze, Ana, Makharadze, Tamta, Gogishvili, Miranda, Melkadze, Tamar, Giorgadze, Davit, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, AG McIntyre, Debra, Perez, Javier, Kaul, Manika, Quek, Ruben G.W., Seebach, Frank, Rietschel, Petra, Pouliot, Jean-Francois
Zdroj: In Lung Cancer July 2024 193
Databáze: ScienceDirect
Externí odkaz: